Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

CLIN-TCR Translating TCR–Antigen Pairing to Clinical Relevance: A Platform for Cancer and Autoimmune Applications

Coordinator
Universita Degli Studi Di Padova, Italy
Runs
1 March 2026 to 31 August 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101292609

What the project is doing

In the project's own words, from its summary on CORDIS.

T cell receptors (TCRs) recognize antigens presented by HLA molecules and are central to immunity; nevertheless our ability to systematically map TCR-antigen pairs is still severely limited. Current approaches—individual antigen assays, multimer staining, or display systems—are either low throughput or biased towards known epitopes, and fail to deliver comprehensive datasets needed for therapeutic and diagnostic applications.

This bottleneck hampers the discovery of clinically relevant TCRs and antigens for cancer immunotherapy and for autoimmune disease monitoring. In our ERC project, we developed a library versus library screening platform that can pair TCRs with their cognate antigens in an unbiased manner. Feasibility was demonstrated using model antigens, and the core technology is already the subject of a patent application filed by our institution.

The goal of this Proof of Concept is to demonstrate the clinical utility of the platform by applying it to two major contexts: (i) TCR and tumor-associated antigen and neoantigen discovery in cancer, and (ii) TCR and autoantigen discovery in autoimmune diseases. By generating and validating datasets of clinically relevant TCR-antigen pairs, the project will establish the platform as a source of novel biomarkers and therapeutic leads.

IP consolidation and a refined exploitation strategy will strengthen its translational potential. The expected outputs are: (1) validated datasets of TCR-antigen pairs with direct clinical relevance; (2) a reinforced intellectual property position; and (3) a detailed strategy guiding future commercial exploitation. This project will open a new avenue for precision medicine by enabling scalable mapping of TCR-antigen interactions in clinically relevant settings.

It has the potential to accelerate biomarker discovery, patient stratification, and the development of next-generation TCR-based therapies and therapeutic vaccination.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di PadovaPadovaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI